Filing Flows › Comparisons › MREO vs SLN
Mereo BioPharma Group vs Silence Therapeutics: MREO and SLN compared
Mereo BioPharma Group is the larger company: $500K of revenue in its latest quarter (Q2 2025) against $422K for Silence Therapeutics (Q1 2026).
Where the money goes: MREO and SLN
Mereo BioPharma Group (MREO) · Q2 2025
Mereo BioPharma Group, Q2 2025: revenue $500K, net loss $14.6M, operating cash flow −$7.7M. The chart follows the revenue to costs, profit and cash.
Silence Therapeutics (SLN) · Q1 2026
Silence Therapeutics, Q1 2026: revenue $422K (+197% year over year), net loss $15.0M, operating cash flow −$15.6M. The chart follows the revenue to costs, profit and cash.
| Mereo BioPharma Group (MREO) | Silence Therapeutics (SLN) | |
|---|---|---|
| Latest quarter | Q2 2025 | Q1 2026 |
| Revenue | $500K | $422K |
| Revenue growth, Y/Y | — | +197% |
| Operating margin | n/m | n/m |
| Net earnings | −$14.6M | −$15.0M |
| Operating cash flow | −$7.7M | −$15.6M |
Questions
Which is bigger, Mereo BioPharma Group or Silence Therapeutics?
Mereo BioPharma Group is the larger company: $500K of revenue in its latest quarter (Q2 2025) against $422K for Silence Therapeutics (Q1 2026).
More: Mereo BioPharma Group earnings · how Mereo BioPharma Group makes money · Silence Therapeutics earnings · how Silence Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2025; 10-Q filed May 7, 2026). Fiscal quarters can end on different dates. Not investment advice.